| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/20/1999 | WO1999024434A1 Fused pyrazine compounds |
| 05/20/1999 | WO1999024433A1 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| 05/20/1999 | WO1999024430A1 Novel camptothecin derivatives |
| 05/20/1999 | WO1999024428A1 Oxazolidinone derivatives and pharmaceutical compositions |
| 05/20/1999 | WO1999024423A1 Piperidine derivatives and their use as tachykinin antagonists |
| 05/20/1999 | WO1999024422A1 Azaring-ether derivatives and their use as nicotinic ach receptor modulators |
| 05/20/1999 | WO1999024421A1 Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
| 05/20/1999 | WO1999024420A1 Pyrimidinone compounds and pharmaceutical compositions containing them |
| 05/20/1999 | WO1999024419A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/20/1999 | WO1999024416A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 05/20/1999 | WO1999024411A1 Receptor with an affinity for compounds of the oxazoline class |
| 05/20/1999 | WO1999024408A1 Heterocyclic compounds having mmp and tnf inhibitory activity |
| 05/20/1999 | WO1999024406A1 Phenyl-alkyl-imidazoles as h3 receptor antagonists |
| 05/20/1999 | WO1999024405A1 H3 receptor ligands of the phenyl-alkyl-imidazoles type |
| 05/20/1999 | WO1999024404A1 Substituted pyridine compounds as anti-inflammatory agents |
| 05/20/1999 | WO1999024401A1 Use of alkylated iminosugars to treat multidrug resistance |
| 05/20/1999 | WO1999024399A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/20/1999 | WO1999024398A2 Urea derivatives and their use as integrin inhibitors |
| 05/20/1999 | WO1999024397A1 Benzocycloheptene derivatives |
| 05/20/1999 | WO1999024394A2 Compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| 05/20/1999 | WO1999024391A1 Radio-opaque polymer biomaterials |
| 05/20/1999 | WO1999024073A1 Pharmaceutical compositions containing cyclodextrins and taxoids |
| 05/20/1999 | WO1999024066A2 Methods and compositions for enhancing immune response and for the production of in vitro mabs |
| 05/20/1999 | WO1999024051A2 Application of vasopressin antagonists for treating disturbances or illnesses of the inner ear |
| 05/20/1999 | WO1999024042A2 Stable antiandrogenic gel composition |
| 05/20/1999 | WO1999024041A1 Penetration enhancing and irritation reducing systems |
| 05/20/1999 | WO1999024040A1 Promoting hormone production |
| 05/20/1999 | WO1999024039A1 Method for reducing mast cell mediated allergic reactions |
| 05/20/1999 | WO1999024038A1 Methods for treatment of disorders of cardiac contractility |
| 05/20/1999 | WO1999024037A1 Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| 05/20/1999 | WO1999024036A1 Skin penetration enhancing components |
| 05/20/1999 | WO1999024035A1 Benzothiazole protein tyrosine kinase inhibitors |
| 05/20/1999 | WO1999024034A1 USE OF DIVALENT CATIONS FOR INHIBITING ERYTHROCYTE DEHYDRATION $i(IN VIVO) |
| 05/20/1999 | WO1999024033A1 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
| 05/20/1999 | WO1999024032A1 Transdermal delivery of 3,4-diarylchromans |
| 05/20/1999 | WO1999024031A1 Pharmaceutical composition comprising 3,4-diarylchromans in low dose |
| 05/20/1999 | WO1999024029A1 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 05/20/1999 | WO1999024027A2 Anti-estrogen plus progestin containing oral contraceptives |
| 05/20/1999 | WO1999024026A2 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
| 05/20/1999 | WO1999024025A2 Non-steroidal anti-inflammatories or cox-ii inhibitors for treatment of tumors in the gastro-intestinal tract |
| 05/20/1999 | WO1999024024A2 Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists |
| 05/20/1999 | WO1999024023A2 FORMULATION OF A COMBINATION COMPRISED OF OPIOID AND α - ADRENERGIC AGONISTS AND THE APPLICATION THEREOF |
| 05/20/1999 | WO1999024022A2 Isoquinoline derivatives for treating disorders associated with 5ht7 receptors |
| 05/20/1999 | WO1999024017A1 Novel oral dosage form for carvedilol |
| 05/20/1999 | WO1999024012A1 Low-ph, acid-containing personal care compositions which exhibit reduced sting |
| 05/20/1999 | WO1999024009A1 Uses of d-xylose, the esters thereof and oligosaccharides containing xylose for improving the functionality of epidermal cells |
| 05/20/1999 | WO1999023996A2 Compositions containing red rice fermentation products, frementation processes and monascus strains therefor |
| 05/20/1999 | WO1999023882A1 Method of treatment of pigmented cancer cells utilizing photodynamic therapy |
| 05/20/1999 | WO1999023881A1 Composition and method for preventing or alleviating migraine headaches |
| 05/20/1999 | WO1999016871A3 Nucleic acid catalysts with endonuclease activity |
| 05/20/1999 | WO1999016753A3 Tricyclic 3-oxo-propanenitrile compounds |
| 05/20/1999 | WO1999015649A3 Composition and method for enhancing paracellular transport across cell layers |
| 05/20/1999 | WO1999015526A3 N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives |
| 05/20/1999 | WO1999015503A3 Process for making diaryl pyridines useful as cox-2 inhibitors |
| 05/20/1999 | WO1999015160A3 Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 05/20/1999 | WO1999010494A3 Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses |
| 05/20/1999 | WO1999009967A3 Cholesterol-lowering therapy |
| 05/20/1999 | WO1999009965A3 Anti-inflammatory agent |
| 05/20/1999 | WO1999008718A3 Bioresorbable compositions for implantable prostheses |
| 05/20/1999 | WO1999007736A3 Lipoprotein-regulating medicaments |
| 05/20/1999 | WO1999007734A3 Hepatitis c inhibitor peptide analogues |
| 05/20/1999 | WO1999007350A3 Chemo-protection |
| 05/20/1999 | WO1999001118A9 Antioxidant enhancement of therapy for hyperproliferative conditions |
| 05/20/1999 | WO1998048785A9 Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| 05/20/1999 | WO1998031796A8 Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons |
| 05/20/1999 | WO1998024806B1 Substituted oxadiazole, thiadiazole and triazole serine protease inhibitors |
| 05/20/1999 | WO1998023574A8 Asiatic acid derivatives and medicines for treating wounds, which contains the same |
| 05/20/1999 | WO1998013007A8 Methods and compositions for lipidization of hydrophilic molecules |
| 05/20/1999 | DE19849652A1 Pharmaceutical composition active against intestinal carcinoma |
| 05/20/1999 | DE19750623A1 New 2H-1-pyran-2-one derivatives useful as anticonvulsants and neuroprotectants |
| 05/20/1999 | DE19750529A1 New heterocyclic alpha-hydroxycarboxylic acid derivatives useful for treating hypertension, chronic coronary insufficiency, asthma, prostate cancer etc. |
| 05/20/1999 | DE19750498A1 Use of inhibitors of sodium-hydrogen ion exchangers for treating CNS conditions |
| 05/20/1999 | DE19750085A1 New 2-phenyl-imidazotriazinone derivatives used for treating cardiovascular, cerebrovascular and urogenital disorders |
| 05/20/1999 | CA2310590A1 Method of treatment of pigmented cancer cells utilizing photodynamic therapy |
| 05/20/1999 | CA2310072A1 Fused pyrazine compounds |
| 05/20/1999 | CA2309923A1 Composition and method for preventing or alleviating migraine headaches |
| 05/20/1999 | CA2309691A1 Drugs, foods or drinks with the use of algae-derived physiologically active substances |
| 05/20/1999 | CA2309690A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| 05/20/1999 | CA2309652A1 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 05/20/1999 | CA2309640A1 Nuclear targeting by means of bacterial proteins |
| 05/20/1999 | CA2309626A1 Compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| 05/20/1999 | CA2309609A1 Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
| 05/20/1999 | CA2309603A1 Receptor with an affinity for compounds of the oxazoline class |
| 05/20/1999 | CA2309557A1 Tumor-specific antigens, methods for their production and their use for immunization and diagnosis |
| 05/20/1999 | CA2309542A1 Novel oral dosage form for carvedilol |
| 05/20/1999 | CA2309360A1 Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis |
| 05/20/1999 | CA2309321A1 Use of alkylated iminosugars to treat multidrug resistance |
| 05/20/1999 | CA2309319A1 Benzothiazole protein tyrosine kinase inhibitors |
| 05/20/1999 | CA2309200A1 Adenosine a1 receptor agonists |
| 05/20/1999 | CA2309199A1 Adensine a1 receptor agonists |
| 05/20/1999 | CA2309177A1 Pyrimidinone compounds and pharmaceutical compositions containing them |
| 05/20/1999 | CA2309162A1 Piperidine derivatives and their use as tachykinin antagonists |
| 05/20/1999 | CA2309123A1 Stable antiandrogenic gel composition |
| 05/20/1999 | CA2309121A1 Phenyl-alkyl-imidazoles as h3 receptor antagonists |
| 05/20/1999 | CA2309117A1 Application of vasopressin antagonists for treating disturbances or illnesses of the inner ear |
| 05/20/1999 | CA2308854A1 Use of divalent cations for inhibiting erythrocyte dehydration in vivo |
| 05/20/1999 | CA2308779A1 Human blood bacterium |
| 05/20/1999 | CA2308716A1 Urea derivatives and their use as integrin inhibitors |
| 05/20/1999 | CA2308586A1 H3 receptor ligands of the phenyl-alkyl-imidazoles type |
| 05/20/1999 | CA2308406A1 Method for reducing mast cell mediated allergic reactions |